pharma · Thyroid eye disease · Thyroid Eye Disease · VRDN
Viridian Pharma
Viridian Pharma Ltd
Viridian Pharma clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 200 Market Street, ELMWOOD PARK, NJ 07407, US
- Founded
- 2017
- Employees
- 2
- Programs
- 13
- Drugs
- 11
- Patents
- 3
Viridian Pharma projects
13 ClinicalTrials.gov programs sponsored by Viridian Pharma.
Viridian Pharma has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
VRDN-001 (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor)
Viridian Pharma Ltd
Thyroid eye disease
1 trial -
VRDN-001 10 mg/kg
Viridian Pharma Ltd
Thyroid Eye Disease
1 trial -
VRDN-001 Phase 3 Cohort (THRIVE)
Viridian Pharma Ltd
Thyroid Eye Disease
1 trial -
VRDN-001-101
Viridian Pharma Ltd
Thyroid eye disease (TED)
1 trial -
VRDN-001-301
Viridian Pharma Ltd
Thyroid eye disease
1 trial -
VRDN-001-302
Viridian Pharma Ltd
Thyroid eye disease
1 trial -
VRDN-003
Viridian Pharma Ltd
Thyroid Eye Disease (TED)
1 trial -
VRDN-003
Viridian Pharma Ltd
Thyroid Eye Disease
3 trials -
VRDN-003-301
Viridian Pharma Ltd
Thyroid eye disease
1 trial -
VRDN-003-302
Viridian Pharma Ltd
Thyroid eye disease
1 trial -
VRDN-003-303
Viridian Pharma Ltd
Thyroid eye disease
1 trial -
Veligrotug
Viridian Pharma Ltd
Thyroid Eye Disease
1 trial -
Veligrotug (VRDN-001)
Viridian Pharma Ltd
Thyroid Eye Disease
1 trial
Frequently asked questions
How many clinical projects does Viridian Pharma have?
13 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.